TP53 and cancer: Although mixed amino acid incorporations into p53 oligomers might create inactive p53 molecules in human cancers (Milner and Medcalf, 1991), there are other clinical syndromes such as skin diseases with a PTC driver gene (Li et al., 2023) where a PTC readthrough in response to medicinal treatment produces a “full-length” protein with activity.